



2 September 2020

## **ASX RELEASE**

### **Security Sale Facility Successfully Completed**

Atlas Arteria (**ASX:ALX**) is pleased to announce the successful completion of its Security Sale Facility ("Sale Facility").

The Sale Facility was announced on 3 July 2020 and enabled securityholders domiciled in the United States who are not "qualified purchasers"<sup>1</sup> to divest their holding in Atlas Arteria stapled securities without incurring any brokerage costs. The Sale Facility also provided for a 15% premium over the average sale price per Stapled Security sold over the three trading day period from 28 August 2020 to 1 September 2020 ("Sale Price"). Stapled Securities of US Retail Securityholders who did not elect to participate in the Sale Facility were compulsorily sold through the Sale Facility in accordance with Atlas Arteria's Constitution and Bye-laws ("Compulsory Transfer").

Atlas Arteria has previously been prevented from accessing US capital markets due to restrictions under the US Investment Company Act. These restrictions applied to Atlas Arteria because of a small number of US Retail Securityholders on its register. With this transaction now completed, Atlas Arteria will be able to access capital from certain existing and new US institutional investors, should it choose to raise capital in the future.

214,191 Stapled Securities were sold through the Sale Facility at an average sale price per Stapled Security of A\$6.52.

Atlas Arteria CEO Graeme Bevans said: "The successful completion of this facility is an important step for Atlas Arteria, enabling our current and new US institutional investors to participate in capital raisings."

Atlas Arteria has subsequently determined to pay a 15% premium to the Sale Price to all US Retail Securityholders who have been divested through the Sale Facility, whether voluntarily or through the Compulsory Transfer. The proceeds of A\$7.50 per Stapled Security (being the Sale Price plus a premium of 15%) will be sent to relevant securityholders on 7 September 2020.

---

<sup>1</sup> As defined in section 2(a)(51) of the US Investment Company Act of 1940

---

**For further information please contact:**

**Investors:**

**Jeanette Royce**

Director, Investor Relations

1800 621 694 / +61 (0)438 493 692

[investors@atlasarteria.com](mailto:investors@atlasarteria.com)

**Media:**

**Lisa Keenan**

Nightingale Advisors

+61 (0)409 150 771

[lisa@nightingleadvisors.com.au](mailto:lisa@nightingleadvisors.com.au)

---

This announcement has been authorised for release by Clayton McCormack, General Counsel and Company Secretary.

**About Atlas Arteria**

Atlas Arteria (ASX:ALX) is a global owner, operator and developer of toll roads, creating value for our investors over the long-term through considered and disciplined management. The roads we own, operate and develop benefit communities through reduced travel time, greater time certainty, reduced fuel consumption and carbon emissions.

Today the Atlas Arteria Group consists of four businesses. We currently own a 31.14% interest in the APRR toll road group in France. Adjacent to the APRR business is the smaller ADELAC business which connects to APRR in south-east France. Together APRR and ADELAC comprise a 2,318km motorway network located in the East and South East of France. In the US, we have 100% of the economic interest in the Dulles Greenway, a 22km toll road in the Commonwealth of Virginia. In Germany, we own 100% of the Warnow Tunnel in the north-east city of Rostock.

[www.atlasarteria.com](http://www.atlasarteria.com)